HCV and HCC: Clinical update and a review of HCC-associated viral mutations in the core gene

Seminars in Liver Disease

Volumn 31, Issue 4, 2011, Pages 347-355

  Ahmad, Jawad ^a   Eng, Francis J ^a   Branch, Andrea D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

core protein; Hepatitis C virus; hepatocellular carcinoma; minicore

Indexed keywords

ALPHA INTERFERON; CORE PROTEIN; PEGINTERFERON; RIBAVIRIN;

CANCER EPIDEMIOLOGY; CANCER RISK; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; ERADICATION THERAPY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; MAINTENANCE THERAPY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; VIRUS CARCINOGENESIS; VIRUS MUTATION;

CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GENES, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; METABOLIC SYNDROME X; OBESITY; POINT MUTATION;

EID: 84455181499     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1297924     Document Type: Review

References (102)

1. El-Serag H B., Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 340 10 745-750 (Pubitemid 29114292)
2. Kew M C. Hepatitis B and C viruses and hepatocellular carcinoma. Clin Lab Med 1996 16 2 395-406 (Pubitemid 26185274)
3. Kim C M., Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991 351 6324 317-320 (Pubitemid 21896589)
4. Nishioka K, Watanabe J, Furuta S et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991 67 2 429-433
5. Bruix J, Barrera J M., Calvet X et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989 2 8670 1004-1006 (Pubitemid 19257915)
6. Colombo M, Kuo G, Choo Q L. et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989 2 8670 1006-1008 (Pubitemid 19257916)
7. Altekruse S F., McGlynn K A., Reichman M E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009 27 9 1485-1491
8. Dominitz J A., Boyko E J., Koepsell T D. et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005 41 1 88-96 (Pubitemid 40066386)
9. Kanwal F, Hoang T, Kramer J R. et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011 140 4 1182-1188, e1
10. Sangiovanni A, Prati G M., Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006 43 6 1303-1310 (Pubitemid 43980109)
11. Tanaka Y, Kurbanov F, Mano S et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006 130 3 703-714 (Pubitemid 43374521)
12. Tanaka H, Imai Y, Hiramatsu N et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008 148 11 820-826 (Pubitemid 351786929)
13. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011 53 3 1020-1022
14. Davila J A., Morgan R O., Richardson P A., Du X L., McGlynn K A., El-Serag H B. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010 52 1 132-141
15. Davila J A., Henderson L, Kramer J R. et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011 154 2 85-93
16. Santi V, Trevisani F, Gramenzi A et al, Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010 53 2 291-297
17. Lok A S., Sterling R K., Everhart J E. et al, HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010 138 2 493-502
18. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli M U. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007 46 5 1350-1356 (Pubitemid 350155516)
19. Lee M H., Yang H I., Lu S N. et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 2010 28 30 4587-4593
20. Kumada T, Toyoda H, Kiriyama S et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol 2009 50 4 729-735
21. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S, JPHC Study Group. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prev 2009 18 1 26-32
22. Maki A, Kono H, Gupta M et al. Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 2007 14 3 1182-1190
23. Suruki R Y., Mueller N, Hayashi K et al. Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev 2006 15 12 2521-2525 (Pubitemid 46048315)
24. Dienstag J L., Ghany M G., Morgan T R. et al, HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011 54 2 396-405
25. Hoefs J C., Shiffman M L., Goodman Z D., Kleiner D E., Dienstag J L., Stoddard A M., HALT-C Trial Group. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C trial. Gastroenterology 2011 141 3 900-908 e1-e2
26. Asahina Y, Tsuchiya K, Tamaki N et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010 52 2 518-527
27. Hassan M M., Spitz M R., Thomas M B. et al. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 2009 50 2 334-341
28. Lok A S., Everhart J E., Di Bisceglie A M., Kim H Y., Hussain M, Morgan T R., HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011 54 2 434-442
29. Ikeda K, Marusawa H, Osaki Y et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007 146 9 649-656 (Pubitemid 351650520)
30. Gelatti U, Covolo L, Franceschini M et al, Brescia HCC Study Group. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005 42 4 528-534 (Pubitemid 40342932)
31. Inoue M, Yoshimi I, Sobue T, Tsugane S, JPHC Study Group. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005 97 4 293-300 (Pubitemid 40310277)
32. Lambrecht R W., Sterling R K., Naishadham D et al, HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011 140 5 1490-1500, e3
33. Nahon P, Sutton A, Rufat P et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008 134 1 102-110 (Pubitemid 350309327)
34. Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S, JPHC Study Group. Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Int J Cancer 2009 124 7 1644-1649
35. Lai M S., Hsieh M S., Chiu Y H., Chen T H. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006 43 6 1295-1302 (Pubitemid 43980108)
36. N'Kontchou G, Paries J, Htar M T. et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006 4 8 1062-1068 (Pubitemid 44137435)
37. Veldt B J., Chen W, Heathcote E J. et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008 47 6 1856-1862 (Pubitemid 351945553)
38. Ohishi W, Fujiwara S, Cologne J B. et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2008 17 4 846-854 (Pubitemid 351536415)
39. Ohki T, Tateishi R, Sato T et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008 6 4 459-464 (Pubitemid 351443115)
40. Chen C L., Yang H I., Yang W S. et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008 135 1 111-121
41. Inoue M, Kurahashi N, Iwasaki M et al, Japan Public Health Center-based Prospective Study Group. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control 2009 20 5 741-750
42. Rossi M, Lipworth L, Maso L D. et al. Dietary glycemic load and hepatocellular carcinoma with or without chronic hepatitis infection. Ann Oncol 2009 20 10 1736-1740
43. Nkontchou G, Bastard J P., Ziol M et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010 53 5 827-833
44. Lok A S., Seeff L B., Morgan T R. et al, HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009 136 1 138-148
45. Lok A S., Everhart J E., Wright E C. et al, HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011 140 3 840-849, quiz e12
46. Shiffman M L., Morishima C, Dienstag J L. et al, HALT-C Trial Group. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009 137 6 1986-1994
47. Morgan T R., Ghany M G., Kim H Y. et al, HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010 52 3 833-844
48. Cardoso A C., Moucari R, Figueiredo-Mendes C et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010 52 5 652-657
49. Bruix J, Poynard T, Colombo M et al, EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011 140 7 1990-1999
50. Tanimoto Y, Tashiro H, Aikata H et al. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol 2011 Epub ahead of print
51. Burd E M. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003 16 1 1-17 (Pubitemid 36114705)
52. Raimondi S, Bruno S, Mondelli M U., Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009 50 6 1142-1154
53. Ray R B., Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000 271 1 197-204 (Pubitemid 30341528)
54. Shan Y, Chen X G., Huang B, Hu A B., Xiao D, Guo Z M. Malignant transformation of the cultured human hepatocytes induced by hepatitis C virus core protein. Liver Int 2005 25 1 141-147 (Pubitemid 40298256)
55. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998 4 9 1065-1067 (Pubitemid 28417341)
56. Naas T, Ghorbani M, Alvarez-Maya I et al. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol 2005 86 Pt 8 2185-2196 (Pubitemid 41057523)
57. Li Z H., Tang Q B., Wang J et al. Hepatitis C virus core protein induces malignant transformation of biliary epithelial cells by activating nuclear factor-kappaB pathway. J Gastroenterol Hepatol 2010 25 7 1315-1320
58. Chen R F., Li Z H., Liu R Y., Kong X H., Tang Q B., Wang J. Malignant transformation of the cultured human normal biliary tract epithelial cells induced by hepatitis C virus core protein. Oncol Rep 2007 17 1 105-110
59. Jin D Y., Wang H L., Zhou Y et al. Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. EMBO J 2000 19 4 729-740 (Pubitemid 30093746)
60. Smirnova I S., Aksenov N D., Kashuba E V. et al. Hepatitis C virus core protein transforms murine fibroblasts by promoting genomic instability. Cell Oncol 2006 28 4 177-190 (Pubitemid 44427401)
61. El-Serag H B., Rudolph K L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 7 2557-2576 (Pubitemid 46890874)
62. Bartosch B, Thimme R, Blum H E., Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009 51 4 810-820
63. Fishman S L., Factor S H., Balestrieri C et al. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res 2009 15 9 3205-3213
64. Ogata S, Nagano-Fujii M, Ku Y, Yoon S, Hotta H. Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol 2002 40 10 3625-3630
65. Rüster B, Zeuzem S, Krump-Konvalinkova V et al. Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. J Med Virol 2001 63 2 128-134 (Pubitemid 32142269)
66. Delhem N, Sabile A, Gajardo R et al. Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein. Oncogene 2001 20 41 5836-5845 (Pubitemid 32937953)
67. Horie C, Iwahana H, Horie T et al. Detection of different quasispecies of hepatitis C virus core region in cancerous and noncancerous lesions. Biochem Biophys Res Commun 1996 218 3 674-681 (Pubitemid 26050722)
68. Alam S S., Nakamura T, Naganuma A et al. Hepatitis C virus quasispecies in cancerous and noncancerous hepatic lesions: the core protein-encoding region. Acta Med Okayama 2002 56 3 141-147 (Pubitemid 135689610)
69. Takahashi K, Iwata K, Matsumoto M et al. Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the progression score revisited. Hepatol Res 2001 20 2 161-171
70. Hung C H., Chen C H., Lee C M. et al. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepat 2008 15 1 58-65
71. Akuta N, Suzuki F, Kawamura Y et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007 46 5 1357-1364 (Pubitemid 350155517)
72. Nakamoto S, Imazeki F, Fukai K et al. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J Hepatol 2010 52 1 72-78
73. Kobayashi M, Akuta N, Suzuki F et al. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010 82 1 41-48
74. Donlin M J., Cannon N A., Yao E et al, Virahep-C Study Group. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007 81 15 8211-8224 (Pubitemid 47101507)
75. Enomoto N, Maekawa S. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 2010 53 1 66-69
76. Okanoue T, Itoh Y, Hashimoto H et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009 44 9 952-963
77. Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007 46 3 403-410 (Pubitemid 46185701)
78. Mori N, Imamura M, Kawakami Y et al, Hiroshima Liver Study Group. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol 2009 81 4 640-649
79. Akuta N, Suzuki F, Hirakawa M et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009 81 3 452-458
80. Akuta N, Suzuki F, Kawamura Y et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007 79 11 1686-1695 (Pubitemid 47479887)
81. Akuta N, Suzuki F, Kawamura Y et al. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007 50 5 361-368 (Pubitemid 350014920)
82. Akuta N, Suzuki F, Sezaki H et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006 78 1 83-90 (Pubitemid 41783847)
83. Akuta N, Suzuki F, Hirakawa M et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009 81 6 1032-1039
84. Funaoka Y, Sakamoto N, Suda G et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol 2011 85 12 5986-5994
85. Fraser C S., Doudna J A. Structural and mechanistic insights into hepatitis C viral translation initiation. Nat Rev Microbiol 2007 5 1 29-38 (Pubitemid 44942301)
86. Fukushi S, Katayama K, Kurihara C et al. Complete 5 noncoding region is necessary for the efficient internal initiation of hepatitis C virus RNA. Biochem Biophys Res Commun 1994 199 2 425-432
87. Hellen C U., Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev 2001 15 13 1593-1612 (Pubitemid 32702581)
88. Honda M, Ping L H., Rijnbrand R C. et al. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology 1996 222 1 31-42 (Pubitemid 26281356)
89. Kieft J S., Zhou K, Jubin R, Doudna J A. Mechanism of ribosome recruitment by hepatitis C IRES RNA. RNA 2001 7 2 194-206 (Pubitemid 33590503)
90. Otto G A., Puglisi J D. The pathway of HCV IRES-mediated translation initiation. Cell 2004 119 3 369-380 (Pubitemid 39423839)
91. Wang C, Sarnow P, Siddiqui A. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J Virol 1993 67 6 3338-3344 (Pubitemid 23143708)
92. McMullan L K., Grakoui A, Evans M J. et al. Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A 2007 104 8 2879-2884 (Pubitemid 46327973)
93. Vassilaki N, Friebe P, Meuleman P et al. Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication. J Virol 2008 82 23 11503-11515
94. Tuplin A, Evans D J., Simmonds P. Detailed mapping of RNA secondary structures in core and NS5B-encoding region sequences of hepatitis C virus by RNase cleavage and novel bioinformatic prediction methods. J Gen Virol 2004 85 Pt 10 3037-3047 (Pubitemid 39360048)
95. Walewski J L., Gutierrez J A., Branch-Elliman W et al. Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. RNA 2002 8 5 557-571 (Pubitemid 34496576)
96. Branch A D., Stump D D., Gutierrez J A., Eng F, Walewski J L. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis 2005 25 1 105-117 (Pubitemid 40322355)
97. Eng F J., Walewski J L., Klepper A L. et al. Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol 2009 83 7 3104-3114
98. Ogura S, Akuta N, Hirakawa M et al. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment. Intervirology 2009 52 4 179-188
99. Eng F J., Yusuke Y, Kopp M et al. Viral mutations that predict treatment failure and liver cancer control expression of the newly-discovered HCV minicore proteins. Paper presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases; October 29November 2, 2010; Boston, MA
100. Chen H M., Tanaka N, Mitani Y et al. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci 2009 100 3 449-456
101. Fridman A L., Tainsky M A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008 27 46 5975-5987
102. Lindkvist A, Ivarsson K, Jernberg-Wiklund H, Paulsson-Karlsson Y. Interferon-induced sensitization to apoptosis is associated with repressed transcriptional activity of the hTERT promoter in multiple myeloma. Biochem Biophys Res Commun 2006 341 4 1141-1148 (Pubitemid 43221784)